The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
G PROTEINS: TRANSDUCERS OF RECEPTOR-GENERATED SIGNALS
Gilman, A. G. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.003151 · Cited by 6,381
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Etienne-Manneville, S., & Hall, A. (2002) · Nature · doi:10.1038/nature01148 · Cited by 4,201
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Takai, Y., Sasaki, T., & Matozaki, T. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.1.153 · Cited by 2,475
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
All ras proteins are polyisoprenylated but only some are palmitoylated
Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,799
The Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
PROTEIN PRENYLATION: Molecular Mechanisms and Functional Consequences
Zhang, F. L., & Casey, P. J. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.001325 · Cited by 1,743
GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors
Rossman, K. L., Der, C. J., & Sondek, J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1587 · Cited by 1,697
ARF proteins: roles in membrane traffic and beyond
D'Souza-Schorey, C., & Chavrier, P. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1910 · Cited by 1,378
Sahai, E., & Marshall, C. J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc725 · Cited by 1,261
Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking
Ridley, A. J. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.08.006 · Cited by 1,178
Rational design and characterization of a Rac GTPase-specific small molecule inhibitor
Gao, Y., Dickerson, J. B., Guo, F., Zheng, J., & Zheng, Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307512101 · Cited by 1,091
Weitz-Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J., Bruns, C., Cottens, S., Takada, Y., & Hommel, U. (2001) · Nature Medicine · doi:10.1038/89058 · Cited by 1,041
Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas
Pasqualucci, L., Neumeister, P., Goossens, T., Nanjangud, G., Chaganti, R. S. K., Küppers, R., & Dalla-Favera, R. (2001) · Nature · doi:10.1038/35085588 · Cited by 1,032
Glucosylation of Rho proteins by Clostridium difficile toxin B
Just, I., Selzer, J., Wilm, M., Eichel-Streiber, C. V., Mann, M., & Aktories, K. (1995) · Nature · doi:10.1038/375500a0 · Cited by 1,032
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors
Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884
Demierre, M.-F., Higgins, P. D. R., Gruber, S. B., Hawk, E., & Lippman, S. M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1751 · Cited by 819
Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W. L., Szawlowski, A., Schoffski, P., Post, S., Verslype, C., Neumann, H., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.112 · Cited by 786
GDIs: central regulatory molecules in Rho GTPase activation
DerMardirossian, C., & Bokoch, G. M. (2005) · Trends in Cell Biology · doi:10.1016/j.tcb.2005.05.001 · Cited by 678
Ras signalling on the endoplasmic reticulum and the Golgi
Chiu, V. K., Bivona, T., Hach, A., Sajous, J. B., Silletti, J., Wiener, H., Johnson, R. L., Cox, A. D., & Philips, M. R. (2002) · Nature Cell Biology · doi:10.1038/ncb783 · Cited by 594 · cited 1×
“Second, although RCE1 and ICMT inhibition cause mislocalization of RAS, it has been shown that farnesylated or geranylgeranylated RAS (specifically NRAS and HRAS) can still signal from other locations besides the plasma membrane (such as the endoplasmic reticulum or Golgi”
BackgroundSelective Inhibition of ras -Dependent Transformation by a Farnesyltransferase Inhibitor
Kohl, N. E., Mosser, S. D., deSolms, S. J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A., & Gibbs, J. B. (1993) · Science · doi:10.1126/science.8316833 · Cited by 579
Wong, W. W.-L., Dimitroulakos, J., Minden, M., & Penn, L. (2002) · Leukemia · doi:10.1038/sj.leu.2402476 · Cited by 578
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers
Cheng, K. W., Lahad, J. P., Kuo, W.-L., Lapuk, A., Yamada, K., Auersperg, N., Liu, J., Smith-McCune, K., Lu, K. H., Fishman, D., et al. (2004) · Nature Medicine · doi:10.1038/nm1125 · Cited by 509
Hoffman, G. R., Nassar, N., & Cerione, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)80670-4 · Cited by 500
Targeting Rab GTPases to distinct membrane compartments
Pfeffer, S., & Aivazian, D. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1500 · Cited by 471
GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila
Bernards, A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00082-3 · Cited by 361
Post-prenylation-processing enzymes as new targets in oncogenesis
Winter-Vann, A. M., & Casey, P. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1612 · Cited by 357
Kawata, S., Yamasaki, E., Nagase, T., Inui, Y., Ito, N., Matsuda, Y., Inada, M., Tamura, S., Noda, S., Imai, Y., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1716 · Cited by 354
Rao, S., Porter, D. C., Chen, X., Herliczek, T., Lowe, M., & Keyomarsi, K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.7797 · Cited by 345
Mo, H., & Elson, C. E. (2004) · Experimental Biology and Medicine · doi:10.1177/153537020422900701 · Cited by 340
Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer
釜井, 隆. (2004) · Medical Entomology and Zoology · Cited by 336
Strategies to overcome resistance to targeted protein kinase inhibitors
Daub, H., Specht, K., & Ullrich, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1579 · Cited by 334
Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer.
Kamai, T., Tsujii, T., Arai, K., Takagi, K., Asami, H., Ito, Y., & Oshima, H. (2003) · PubMed · Cited by 301
Ezrin/radixin/moesin proteins and Rho GTPase signalling in leucocytes
Ivetic, A., & Ridley, A. J. (2004) · Immunology · doi:10.1111/j.1365-2567.2004.01882.x · Cited by 298
Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors
Basso, A. D., Kirschmeier, P., & Bishop, W. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500012-jlr200 · Cited by 297
Structure of the human ADP-ribosylation factor 1 complexed with GDP
Carlos Amor, J., Harrison, D. H., Kahn, R. A., & Ringe, D. (1994) · Nature · doi:10.1038/372704a0 · Cited by 295
McTaggart, S. J. (2006) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s00018-005-5298-6 · Cited by 293
The Role of Statins in Cancer Therapy
Hindler, K., Cleeland, C. S., Rivera, E., & Collard, C. D. (2006) · The Oncologist · doi:10.1634/theoncologist.11-3-306 · Cited by 291
Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization
Cancelas, J. A., Lee, A. W., Prabhakar, R., Stringer, K. F., Zheng, Y., & Williams, D. A. (2005) · Nature Medicine · doi:10.1038/nm1274 · Cited by 278
Development of Farnesyl Transferase Inhibitors: A Review
Appels, N. M. G. M., Beijnen, J. H., & Schellens, J. H. M. (2005) · The Oncologist · doi:10.1634/theoncologist.10-8-565 · Cited by 272
Requirement for Arf6 in breast cancer invasive activities
Hashimoto, S., Onodera, Y., Hashimoto, A., Tanaka, M., Hamaguchi, M., Yamada, A., & Sabe, H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401753101 · Cited by 270
Scott Reid, T., Terry, K. L., Casey, P. J., & Beese, L. S. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.08.056 · Cited by 264
Pillé, J.-Y., Denoyelle, C., Varet, J., Bertrand, J.-R., Soria, J., Opolon, P., Lu, H., Pritchard, L.-L., Vannier, J.-P., Malvy, C., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.08.029 · Cited by 263
Du, W., Lebowitz, P. F., & Prendergast, G. C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1831 · Cited by 248
Rao, S., Cunningham, D., de Gramont, A., Scheithauer, W., Smakal, M., Humblet, Y., Kourteva, G., Iveson, T., Andre, T., Dostalova, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.037 · Cited by 244
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336
Hoover, R. R., Mahon, F.-X., Melo, J. V., & Daley, G. Q. (2002) · Blood · doi:10.1182/blood.v100.3.1068 · Cited by 241
Lobell, R. B., Omer, C. A., Abrams, M. T., Bhimnathwala, H., Brucker, M. J., Buser, C. A., Davide, J. P., DeSolms, S. J., Dinsmore, C. J., Ellis-Hutchings, M., et al. (2001) · PubMed · Cited by 239
Kourlas, P. J., Strout, M. P., Becknell, B., Veronese, M. L., Croce, C. M., Theil, K. S., Krahe, R., Ruutu, T., Knuutila, S., Bloomfield, C. D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040569197 · Cited by 234
Farnesyltransferase Inhibitors Alter the Prenylation and Growth-stimulating Function of RhoB
Lebowitz, P. F., Casey, P. J., Prendergast, G. C., & Thissen, J. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.25.15591 · Cited by 216
GTPase activating proteins: critical regulators of intracellular signaling
Donovan, S., Shannon, K. M., & Bollag, G. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(01)00041-5 · Cited by 215
Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
Moasser, M. M., Sepp-Lorenzino, L., Kohl, N. E., Oliff, A., Balog, A., Su, D.-S., Danishefsky, S. J., & Rosen, N. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1369 · Cited by 210
Poppe, D., Tiede, I., Fritz, G., Becker, C., Bartsch, B., Wirtz, S., Strand, D., Tanaka, S., Galle, P. R., Bustelo, X. R., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.640 · Cited by 204
Chen, Z., Sun, J., Pradines, A., Favre, G., Adnane, J., & Sebti, S. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000145200 · Cited by 198
van Beek, E., Pieterman, E., Cohen, L., Löwik, C., & Papapoulos, S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0224 · Cited by 195
The small GTPase Ran: interpreting the signs
Quimby, B. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00046-2 · Cited by 194
Arf GAPs: multifunctional proteins that regulate membrane traffic and actin remodelling
Randazzo, P. A., & Hirsch, D. S. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2003.09.012 · Cited by 191
Rho GTPases: Promising Cellular Targets for Novel Anticancer Drugs
Fritz, G., & Kaina, B. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906775471752 · Cited by 188
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
Bergo, M. O., Gavino, B. J., Hong, C., Beigneux, A. P., McMahon, M., Casey, P. J., & Young, S. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200418829 · Cited by 180
Specific Contributions of the Small GTPases Rho, Rac, and Cdc42 to Dbl Transformation
Lin, R., Cerione, R. A., & Manor, D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23633 · Cited by 180
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
Bergö, M. O., Gavino, B. J., Hong, C., Beigneux, A. P., McMahon, M., Casey, P. J., & Young, S. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18829 · Cited by 180
Mechanism of the receptor-catalyzed activation of heterotrimeric G proteins
Oldham, W. M., Van Eps, N., Preininger, A. M., Hubbell, W. L., & Hamm, H. E. (2006) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1129 · Cited by 179
Winter-Vann, A. M., Baron, R. A., Wong, W., dela Cruz, J., York, J. D., Gooden, D. M., Bergo, M. O., Young, S. G., Toone, E. J., & Casey, P. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408107102 · Cited by 178
Rab proteins and endocytic trafficking: potential targets for therapeutic intervention
Stein, M., Dong, J., & Wandinger‐Ness, A. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.07.009 · Cited by 178
Human RhoGAP domain‐containing proteins: structure, function and evolutionary relationships
Peck, J., Douglas, G., Wu, C. H., & Burbelo, P. D. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03331-8 · Cited by 176
Lancet, J. E., Gojo, I., Gotlib, J., Feldman, E. J., Greer, J., Liesveld, J. L., Bruzek, L. M., Morris, L., Park, Y., Adjei, A. A., et al. (2007) · Blood · doi:10.1182/blood-2006-04-014357 · Cited by 175
Jiang, W. G., Watkins, G., Lane, J., Cunnick, G. H., Douglas-Jones, A. G., Mokbel, K., & Mansel, R. E. (2003) · PubMed · Cited by 172
Postprenylation CAAX Processing Is Required for Proper Localization of Ras but Not Rho GTPases
Michaelson, D., Ali, W., Chiu, V. K., Bergo, M., Silletti, J., Wright, L., Young, S. G., & Philips, M. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-11-0960 · Cited by 169
Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities
Onodera, Y., Hashimoto, S., Hashimoto, A., Morishige, M., Mazaki, Y., Yamada, A., Ogawa, E., Adachi, M., Sakurai, T., Manabe, T., et al. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600588 · Cited by 168
Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery
Pommier, Y., & Cherfils, J. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.01.008 · Cited by 165
Basso, A. D., Mirza, A., Liu, G., Long, B. J., Bishop, W. R., & Kirschmeier, P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503763200 · Cited by 162
Macdonald, J. S., McCoy, S., Whitehead, R. P., Iqbal, S., Wade, J. L., Giguere, J. K., & Abbruzzese, J. L. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-2908-y · Cited by 154
MacKeigan, J. P., Clements, C. M., Lich, J. D., Pope, R. M., Hod, Y., & Ting, J. P. ‐. (2003) · PubMed · Cited by 152
Winter-Vann, A. M., Kamen, B. A., Bergö, M. O., Young, S. G., Melnyk, S., James, S. J., & Casey, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1135239100 · Cited by 146
Kato‐Stankiewicz, J., Hakimi, I., Zhi, G., Zhang, J., Serebriiskii, I. G., Guo, L., Edamatsu, H., Koide, H., Menon, S., Eckl, R. W., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222222699 · Cited by 143
Absence of the CAAX Endoprotease Rce1: Effects on Cell Growth and Transformation
Bergö, M. O., Ambroziak, P., Gregory, C., George, A. M., Otto, J. C., Kim, E. J.-H., Nagase, H., Casey, P. J., Balmain, A., & Young, S. G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.1.171-181.2002 · Cited by 142
Changes in gene expression during progression of ovarian carcinoma
Tapper, J., Kettunen, E., El-Rifai, W. M., Seppälä, M. T., Andersson, L. C., & Knuutila, S. (2001) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00386-7 · Cited by 141
Emerging anti-cancer molecular mechanisms of aminobisphosphonates
Caraglia, M., Santini, D., Marra, M., Vincenzi, B., Tonini, G., & Budillon, A. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01094 · Cited by 140
Phase II Study of High-Dose Lovastatin in Patients with Advanced Gastric Adenocarcinoma
Kim, W. S., Kim, M. M., Choi, H. J., Yoon, S., Lee, M. H., Park, K., Park, C. H., & Kang, W. K. (2001) · Investigational New Drugs · doi:10.1023/a:1006481423298 · Cited by 137
RhoGDIs Revisited: Novel Roles in Rho Regulation
Dransart, E., Olofsson, B., & Cherfils, J. (2005) · Traffic · doi:10.1111/j.1600-0854.2005.00335.x · Cited by 136
Lackner, M. R., Kindt, R. M., Carroll, P. M., Brown, K. A., Cancilla, M. R., Chen, C., de Silva, H., Franke, Y., Guan, B., Heuer, T., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.024 · Cited by 136
Preudhomme, C., Roumier, C., Hildebrand, M. P., Dallery-Prudhomme, E., Lantoine, D., Laï, J. L., Daudignon, A., Adenis, C., Bauters, F., Fenaux, P., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203521 · Cited by 135
Kleer, C. G., Griffith, K. A., Sabel, M. S., Gallagher, G., van Golen, K. L., Wu, Z.-F., & Merajver, S. D. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-4170-6 · Cited by 134
He, H., Dai, F., Yu, L., She, X., Zhao, Y. B., Jiang, J., Chen, X., & Zhao, S. (2002) · Gene Expression · doi:10.3727/000000002783992406 · Cited by 132
Familial Cancer Associated with a Polymorphism inARLTS1
Calin, G. A., Trapasso, F., Shimizu, M., Dumitru, C. D., Yendamuri, S., Godwin, A. K., Ferracin, M., Bernardi, G., Chatterjee, D., Baldassarre, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042280 · Cited by 132
Isoprenoid-Mediated Inhibition of Mevalonate Synthesis: Potential Application to Cancer
Elson, C. E., Peffley, D. M., Hentosh, P., & Mo, H. (1999) · Proceedings of The Society for Experimental Biology and Medicine · doi:10.1046/j.1525-1373.1999.d01-87.x · Cited by 129
Spatio-temporal segregation of Ras signals: one ship, three anchors, many harbors
Rocks, O., Lorentzen, A., & Bastiaens, P. I. H. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.06.007 · Cited by 127
Lobell, R. B., Liu, D., Buser, C. A., Davide, J. P., DePuy, E., Hamilton, K., Koblan, K. S., Lee, Y., Mosser, S. D., Motzel, S. L., et al. (2002) · PubMed · Cited by 121
Comparison of potential markers of farnesyltransferase inhibition.
Adjei, A. A., Davis, J. N., Erlichman, C., Svingen, P. A., & Kaufmann, S. H. (2000) · PubMed · Cited by 119
Leung, T. H.-Y., Ching, Y.-P., Yam, J. W. P., Wong, C., Yau, T.-O., Jin, D., & Ng, I. O. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504501102 · Cited by 115
Shi, B., Yaremko, B., Hajian, G., Terracina, G., Bishop, W. R., Liu, M., & Nielsen, L. L. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000170 · Cited by 113
Tabancay, A. P., Gau, C., Machado, I. M. P., Uhlmann, E. J., Gutmann, D. H., Guo, L., & Tamanoi, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306553200 · Cited by 110
Coxon, F. P., Ebetino, F. H., Mules, E. H., Seabra, M. C., McKenna, C. E., & Rogers, M. J. (2005) · Bone · doi:10.1016/j.bone.2005.04.021 · Cited by 109
Edamatsu, H., Gau, C., Nemoto, T., Guo, L., & Tamanoi, F. (2000) · Oncogene · doi:10.1038/sj.onc.1203625 · Cited by 107
Alendronate Disturbs Vesicular Trafficking in Osteoclasts
Alakangas, A., Selander, K. S., Mulari, M. T. K., Halleen, J. M., Lehenkari, P. P., Mönkkönen, J., Salo, J., & nen, K. V. N. (2002) · Calcified Tissue International · doi:10.1007/s002230010047 · Cited by 104
Knox, J. J., Siu, L. L., Chen, E. X., Dimitroulakos, J., Kamel‐Reid, S., Moore, M. J., Chin, S. F., Irish, J., Laframboise, S., & Oza, A. M. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.12.013 · Cited by 101
The endocytic catalysts, Rab5a and Rab7, are tandem regulators of thyroid hormone production
Croizet-Berger, K., Daumerie, C., COUVREUR, M., Courtoy, P. J., & van den Hove, M.-F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122187699 · Cited by 97
Dual Specificity of the Interfacial Inhibitor Brefeldin A for Arf Proteins and Sec7 Domains
Zeeh, J., Zeghouf, M., Grauffel, C., Guibert, B., Martin, E., Dejaegere, A. P., & Cherfils, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600149200 · Cited by 96
Adjei, A. A., Davis, J. N., Bruzek, L. M., Erlichman, C., & Kaufmann, S. H. (2001) · PubMed · Cited by 95
Neville-Webbe, H. L., Evans, C. A., Coleman, R. E., & Holen, I. (2006) · Tumor Biology · doi:10.1159/000092489 · Cited by 91
Wolf, R. M., Draghi, N. A., Liang, X., Dai, C., Uhrbom, L., Eklöf, C., Westermark, B., Holland, E. C., & Resh, M. D. (2003) · Genes & Development · doi:10.1101/gad.1040003 · Cited by 89
Maeda, M., Matsui, T., Imamura, M., Tsukita, S., & Tsukita, S. (1999) · Oncogene · doi:10.1038/sj.onc.1202871 · Cited by 86
Ashby, M. N. (1998) · Current Opinion in Lipidology · doi:10.1097/00041433-199804000-00004 · Cited by 85
Martin, N. E., Brunner, T. B., Kiel, K. D., DeLaney, T. F., Regine, W. F., Mohiuddin, M., Rosato, E. F., Haller, D. G., Stevenson, J. P., Smith, D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0248 · Cited by 83
Tiam1 mutations in human renal-cell carcinomas
Engers, R., Zwaka, T. P., Gohr, L. G., Weber, A., Gerharz, C., & Gabbert, H. E. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001101)88:3<369::aid-ijc8>3.0.co;2-k · Cited by 82
van der Spek, E., Bloem, A. C., van de Donk, N. W. C. J., Bogers-Boer, L., van der Griend, R., Mh, K., de Weerdt, O., Wittebol, S. H., & Lokhorst, H. M. (2006) · PubMed · Cited by 75
Schmidt, S., Diriong, S., Méry, J., Fabbrizio, E., & Debant, A. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02928-9 · Cited by 75
Peterson, Y. K., Kelly, P., Weinbaum, C., & Casey, P. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600168200 · Cited by 74
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro
Jørgensen, H. G., Allan, E. K., Graham, S. M., Godden, J., Richmond, L., Elliott, M. A., Mountford, J. C., Eaves, C. J., & Holyoake, T. L. (2005) · Leukemia · doi:10.1038/sj.leu.2403785 · Cited by 70
Ullén, A., Lennartsson, L., Harmenberg, U., Hjelm-Eriksson, M., Kälkner, K. M., Lennernäs, B., & Nilsson, S. F. (2005) · Acta Oncologica · doi:10.1080/02841860510029617 · Cited by 66
Mechanisms of Disease: preclinical reports of antineoplastic synergistic action of bisphosphonates
Santini, D., Caraglia, M., Vincenzi, B., Holen, I., Scarpa, S., Budillon, A., & Tonini, G. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0520 · Cited by 63
Zeghouf, M., Guibert, B., Zeeh, J., & Cherfils, J. (2005) · Biochemical Society Transactions · doi:10.1042/bst0331265 · Cited by 62
Isoprenylcysteine Carboxyl Methyltransferase Activity Modulates Endothelial Cell Apoptosis
Kramer, K., Harrington, E. O., Lü, Q., Bellas, R. E., Newton, J., Sheahan, K. L., & Rounds, S. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-07-0390 · Cited by 55
Caraglia, M., Budillon, A., Tagliaferri, P., et al. (2005) · Current Drug Targets · doi:10.2174/1389450053765833 · Cited by 53
Reid, T. S., Long, S. B., & Beese, L. S. (2004) · Biochemistry · doi:10.1021/bi049280b · Cited by 51 · cited 1×
“The CAAX mimetic FTI L778123 has been shown to bear significant inhibitory activity against GGTase I (besides FTase”
BackgroundBudman, D. R., & Calabro, A. R. (2006) · Oncology · doi:10.1159/000093006 · Cited by 48
Morgan, M. A., Sebil, T., Aydilek, E., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05696.x · Cited by 47
Doisneau-Sixou, S. F., Cestac, P., Faye, J., Favre, G., & Sutherland, R. L. (2003) · International Journal of Cancer · doi:10.1002/ijc.11263 · Cited by 46
Law, B. K., Nørgaard, P. H., & Moses, H. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.15.10796 · Cited by 45
Russo, P., Malacarne, D., Falugi, C., Trombino, S., & O'Connor, P. M. (2002) · International Journal of Cancer · doi:10.1002/ijc.10461 · Cited by 43
Influencing Cellular Transformation by Modulating the Rates of GTP Hydrolysis by Cdc42
Fidyk, N. J., Wang, J.-B., & Cerione, R. A. (2006) · Biochemistry · doi:10.1021/bi060365h · Cited by 39
Morgan, M. A., Wegner, J., Aydilek, E., Ganser, A., & Reuter, C. W. (2003) · Leukemia · doi:10.1038/sj.leu.2403022 · Cited by 39
Melisi, D., Caputo, R., Damiano, V., et al. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01061 · Cited by 38
Rho GDP dissociation inhibitors as potential targets for anticancer treatment
Zhang, B. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2006.06.001 · Cited by 37
Farnesyltransferase Inhibitors Reverse Taxane Resistance
Marcus, A. I., O’Brate, A., Buey, R. M., Zhou, J., Thomas, S. L., Khuri, F. R., Andreu, J. M., Díaz, F., & Giannakakou, P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0699 · Cited by 36
Non-peptidic, non-prenylic inhibitors of the prenyl protein-specific protease Rce1
Schlitzer, M., Winter-Vann, A. M., & Casey, P. J. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00685-5 · Cited by 30
Manser, E. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00268-x · Cited by 30
Hitting the Hot Spots of Cell Signaling Cascades
Grubb, G. J. J. (2006) · Science · doi:10.1126/science.1126903 · Cited by 27
Zoledronate synergises with imatinib mesylate to inhibit Ph+ primary leukaemic cell growth
Segawa, H., Kimura, S. H., Kuroda, J., Sato, K., Yokota, A., Kawata, E., Kamitsuji, Y., Ashihara, E., Yuasa, T., Fujiyama, Y., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05648.x · Cited by 27
Blumenschein, G. R., Ludwig, C., Thomas, G., Tan, E., Fanucchi, M., Santoro, A., Crawford, J., Breton, J. L., O’Brien, M., & Khuri, F. R. (2005) · Lung Cancer · doi:10.1016/s0169-5002(05)80215-6 · Cited by 24
Paolo, A. D., Danesi, R., Caputo, S., Macchia, M., Lastella, M., Boggi, U., Mosca, F., Marchetti, A., & Tacca, M. D. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1820 · Cited by 23
Synergism of Aminobisphosphonates and Farnesyl Transferase Inhibitors on Tumor Metastasis
Andela, V. B., Rosenblatt, J. D., Schwarz, E. M., Puzas, E. J., Keefe, R. J. O., & Rosier, R. N. (2002) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-200204000-00027 · Cited by 22
The Dbl Homology Domain of BCR Is Not a Simple Spacer in P210BCR-ABL of the Philadelphia Chromosome
Kin, Y., Li, G., Shibuya, M., & Maru, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105484200 · Cited by 19
Hydrophilic Anilinogeranyl Diphosphate Prenyl Analogues Are Ras Function Inhibitors
Roberts, M. J., Troutman, J. M., Chehade, K. A. H., Cha, H. C., Kao, J. P. Y., Huang, X., Zhan, C., Peterson, Y. K., Subramanian, T., Srinivasan, K., et al. (2006) · Biochemistry · doi:10.1021/bi061704+ · Cited by 17
CHEN, Y. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb09405.x · Cited by 13
Leow, J., Baron, R., Casey, P. J., & Go, M. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.11.030 · Cited by 10
Cited by
Santos, C. R., & Schulze, A. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08644.x · Cited by 1,335
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities
Huang, B., Song, B.-L., & Xu, C. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0174-0 · Cited by 921
Okayama, H., Kohno, T., Ishii, Y., Shimada, Y., Shiraishi, K., Iwakawa, R., Furuta, K., Tsuta, K., Shibata, T., Yamamoto, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1403 · Cited by 874
Subra, C., Grand, D., Laulagnier, K., Stella, A., Lambeau, G., Paillasse, M., De Medina, P., Monsarrat, B., Perret, B., Silvente-Poirot, S., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m003657 · Cited by 633
Metadata
- Authors
- Konstantinopoulos, P. A., Karamouzis, M. V., & Papavassiliou, A. G.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-07
- Volume
- 6
- Issue
- 7
- Pages
- 541-555
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2049662137
- Cited by
- 451
- References
- 137
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.